We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

38 hedge funds and large institutions have $71.4M invested in Ibere Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

19% more funds holding

Funds holding: 32 → 38 (+6)

17% more capital invested

Capital invested by funds: $61.1M → $71.4M (+$10.3M)

Holders
38
Holders Change
+6
Holders Change %
+18.75%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
8
Reduced
4
Closed
–
Calls
$89K
Puts
–
Net Calls
+$89K
Net Calls Change
+$15K

Top Buyers

Rank Fund Capital Flow
1
CCA
Castle Creek Arbitrage
Colorado
+$2.45M
2
Citadel Advisors
Citadel Advisors
Florida
+$2.19M
3
BCM
Basso Capital Management
Connecticut
+$1.35M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.32M
5
SSA
Schonfeld Strategic Advisors
New York
+$1.31M

Top Sellers

Rank Fund Capital Flow
1
OPU
Omni Partners US
California
-$151K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$45.9K
3
GCL
Glazer Capital LLC
New York
-$4.8K
4
AM
Ampfield Management
New York
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$7.53M +$2.19M +226,742 +41%
Hudson Bay Capital Management
2
Hudson Bay Capital Management
Connecticut
$5.98M -$45.9K -4,749 -0.8%
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$4.84M – – –
LA
4
Linden Advisors
New York
$4.36M – – –
Marshall Wace
5
Marshall Wace
United Kingdom
$4.36M – – –
SC
6
Sculptor Capital
New York
$4.12M – – –
SCC
7
Spring Creek Capital
Kansas
$3.88M – – –
VI
8
Vestcor Inc
New Brunswick, Canada
$3.88M – – –
Millennium Management
9
Millennium Management
New York
$3.26M +$1.01M +104,000 +45%
MCM
10
Moore Capital Management
New York
$2.91M – – –
RCM
11
Radcliffe Capital Management
Pennsylvania
$2.91M – – –
Nomura Holdings
12
Nomura Holdings
Japan
$2.74M – – –
CCA
13
Castle Creek Arbitrage
Colorado
$2.46M +$2.45M +253,446 New
MP
14
Mangrove Partners
Connecticut
$1.94M – – –
PMAM
15
Picton Mahoney Asset Management
Ontario, Canada
$1.94M – – –
BCM
16
Basso Capital Management
Connecticut
$1.65M +$1.35M +139,819 +462%
Wells Fargo
17
Wells Fargo
California
$1.62M – – –
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$1.56M +$1.32M +136,539 +546%
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$1.45M – – –
SSA
20
Schonfeld Strategic Advisors
New York
$1.31M +$1.31M +135,445 New
FTCM
21
Fir Tree Capital Management
New York
$797K – – –
AA
22
AQR Arbitrage
Connecticut
$745K +$18.4K +1,900 +3%
WA
23
Whitebox Advisors
Minnesota
$727K – – –
WRBC
24
W.R. Berkley Corp
Connecticut
$666K – – –
OPU
25
Omni Partners US
California
$567K -$151K -15,591 -21%
1
2

IBER Hedge Fund Activity: Q3 2021 in Review

38 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q3 2021, worth a combined $71.4M — up 17% from $61.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new IBER positions and 0 closed out — a net gain of 6 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was Castle Creek Arbitrage, opening a new position worth an estimated $2.45M. The largest seller was Omni Partners US, cutting an estimated $151K.

  • 38 institutional investors held Ibere Pharmaceuticals (IBER) as of Q3 2021, up from 32 in Q2 2021.
  • Funds reported $71.4M of Ibere Pharmaceuticals stock for Q3 2021, up 17% quarter-over-quarter.
  • 6 funds opened new Ibere Pharmaceuticals positions in Q3 2021 and 0 closed out, a net change of +6 holders.
  • The largest Ibere Pharmaceuticals buyer in Q3 2021 was Castle Creek Arbitrage, an estimated $2.45M added.
  • The largest Ibere Pharmaceuticals seller in Q3 2021 was Omni Partners US, an estimated $151K sold.

Based on aggregated 13F filings for Q3 2021.